Lipoprotein News and Research

RSS

A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their derivatives may be covalently or non-covalently bound to the proteins.

Statins for erectile dysfunction proposed

Family doctors should offer men with erectile dysfunction treatment with a statin – not only to improve their quality of life but also to reduce their future cardiovascular risk.

28 Jun 2012

New scoring system may better identify adolescents with metabolic syndrome

Researchers have developed a new scoring system that may better identify adolescents with the metabolic syndrome, a group at increased risk of later developing Type 2 diabetes and heart disease.

26 Jun 2012

OSA underdiagnosed among primary care diabetes patients

Obstructive sleep apnea is commonly underdiagnosed in patients with Type 2 diabetes in primary care, suggest study findings.

22 Jun 2012

LDL particles may be a more accurate measure of early-stage atherosclerosis

LipoScience, Inc., today announced publication of a clinical study in the current issue of Atherosclerosis suggesting that low density lipoprotein (LDL) particles may be a more accurate measure of early-stage (subclinical) atherosclerosis than LDL cholesterol among retired National Football League (NFL) players.

19 Jun 2012

Women may need stronger lipid-lowering regimens

Women who are at high risk for cardiovascular disease are significantly less likely to achieve their lipid-lowering treatment goals than their male counterparts, show findings from a Chinese study.

7 Jun 2012

ADACTA trial: Tocilizumab more effective than adalimumab in treating RA

Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treatment of rheumatoid arthritis (RA) based on change from baseline in DAS28 (-3.3 vs. -1.8, p<0.0001) at week 24.

7 Jun 2012

Patients with normal lipoprotein(a) levels may retain risk of atherosclerosis due to elevated LDL-P number

LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, today announced results from a clinical study demonstrating that patients with normal levels of lipoprotein(a) may retain significant risk of atherosclerosis due to an elevated low density lipoprotein particle (LDL-P) number.

2 Jun 2012

Lilly, Kowa announce results from PREVAIL U.S. study

Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.

2 Jun 2012

People with fatty livers need to lose weight

Exercising moderately for 150 to 300 minutes a week does not improve lipoprotein metabolism in obese people with nonalcoholic fatty lipid disease, show findings from a US study.

31 May 2012

BHD launches Statin Induced Myopathy Genotype test

Boston Heart Diagnostics (BHD) announced today the commercial launch of the Statin Induced Myopathy (SLCO1B1) Genotype test licensed from the University of Oxford's technology commercialization company Isis Innovation.

31 May 2012

FDA accepts NDA filing for KYNAMRO to treat HoFH

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., announced today that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for KYNAMRO (mipomersen sodium) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).

29 May 2012

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Sanofi and Regeneron Pharmaceuticals, Inc. today announced additional positive results from a Phase 2 trial of SAR236553/REGN727 in patients with heterozygous familial hypercholesterolemia (heFH).

28 May 2012

Research roundup: Do mandatory screening laws affect disparities?; Mass. health law, 6 years later

Since Massachusetts passed its own expansive health law, the state's uninsured rate has dropped and access to care has dramatically improved. But as this brief notes, two major issues remain. Massachusetts will have to find ways to contain health care costs -- now under discussion in the state legislature -- as well as align itself with the federal health law. In the process, other states "can draw on some of the state's early successes and challenges"

25 May 2012

Obese patients with fatty liver disease show only small benefit on lipoprotein levels with moderate exercise

New research found that moderate exercise does not improve lipoprotein concentrations in obese patients with non alcoholic fatty liver disease (NAFLD). Results published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, report that moderate physical activity produces only a small decrease in triglyceride and alanine transaminase (ALT) levels.

24 May 2012

Palpitations, hypertension strongest risk factors for AF

A large cohort study has found that the strongest risk factors for atrial fibrillation in both men and women were a history of palpitations and hypertension. While hypertension is a well known risk factor for AF, the investigators note that "the impact of self-reported palpitations on later occurrence of AF has not been documented earlier".

16 May 2012

'Good' cholesterol may not protect against coronary heart disease

A new study by Harvard School of Public Health (HSPH) researchers has found that a subclass of high-density lipoprotein (HDL) cholesterol, the so-called "good" cholesterol, may not protect against coronary heart disease (CHD) and in fact may be harmful.

8 May 2012

New information about biological outcomes and commuting distance

As populations move even further away from urban centers, more people spend longer hours behind the wheel on their way to and from work. While sedentary behavior is known to have adverse effects on cardiovascular and metabolic health, the impact of long commutes by automobile are less understood. A new study has found that greater commuting distances are associated with decreased cardiorespiratory fitness (CRF), increased weight, and other indicators of metabolic risk.

8 May 2012